Amelioration of Acute Kidney Injury in Lipopolysaccharide-Induced Systemic Inflammatory Response Syndrome by an Aldose Reductase Inhibitor, Fidarestat

Systemic inflammatory response syndrome is a fatal disease because of multiple organ failure. Acute kidney injury is a serious complication of systemic inflammatory response syndrome and its genesis is still unclear posing a difficulty for an effective treatment. Aldose reductase (AR) inhibitor is recently found to suppress lipopolysaccharide (LPS)-induced cardiac failure and its lethality. We studied the effects of AR inhibitor on LPS-induced acute kidney injury and its mechanism.Mice were injected with LPS and the effects of AR inhibitor (Fidarestat 32 mg/kg) before or after LPS injection were examined for the mortality, severity of renal failure and kidney pathology. Serum concentrations of cytokines (interleukin-1β, interleukin-6, monocyte chemotactic protein-1 and tumor necrosis factor-α) and their mRNA expressions in the lung, liver, spleen and kidney were measured. We also evaluated polyol metabolites in the kidney.Mortality rate within 72 hours was significantly less in LPS-injected mice treated with AR inhibitor both before (29%) and after LPS injection (40%) than untreated mice (90%). LPS-injected mice showed marked increases in blood urea nitrogen, creatinine and cytokines, and AR inhibitor treatment suppressed the changes. LPS-induced acute kidney injury was associated with vacuolar degeneration and apoptosis of renal tubular cells as well as infiltration of neutrophils and macrophages. With improvement of such pathological findings, AR inhibitor treatment suppressed the elevation of cytokine mRNA levels in multiple organs and renal sorbitol accumulation.AR inhibitor treatment ameliorated LPS-induced acute kidney injury, resulting in the lowered mortality

Testing devices for the prevention and treatment of stroke and its complications

We are entering a challenging but exciting period when many new interventions may appear for stroke based on the use of devices. Hopefully these will lead to improved outcomes at a cost that can be afforded in most parts of the world. Nevertheless, it is vital that lessons are learnt from failures in the development of pharmacological interventions (and from some early device studies), including inadequate preclinical testing, suboptimal trial design and analysis, and underpowered studies. The device industry is far more disparate than that seen for pharmaceuticals; companies are very variable in size and experience in stroke, and are developing interventions across a wide range of stroke treatment and prevention. It is vital that companies work together where sales and marketing are not involved, including in understanding basic stroke mechanisms, prospective systematic reviews, and education of physicians. Where possible, industry and academics should also work closely together to ensure trials are designed to be relevant to patient care and outcomes. Additionally, regulation of the device industry lags behind that for pharmaceuticals, and it is critical that new interventions are shown to be safe and effective rather than just feasible. Phase IV postmarketing surveillance studies will also be needed to ensure that devices are safe when used in the ‘real-world’ and to pick up uncommon adverse events

Ion homeostasis in the Chloroplast

peer reviewedThe chloroplast is an organelle of high demand for macro- and micro-nutrient ions, which are required for the maintenance of the photosynthetic process. To avoid deficiency while preventing excess, homeostasis mechanisms must be tightly regulated. Here, we describe the needs for nutrient ions in the chloroplast and briefly highlight their functions in the chloroplastidial metabolism. We further discuss the impact of nutrient deficiency on chloroplasts and the acclimation mechanisms that evolved to preserve the photosynthetic apparatus. We finally present what is known about import and export mechanisms for these ions. Whenever possible, a comparison between cyanobacteria, algae and plants is provided to add an evolutionary perspective to the description of ion homeostasis mechanisms in photosynthesis

SYNTHESIS AND STRUCTURAL CHARACTERIZATION OF A NEW METHYLENE BRIDGED DOUBLE BUTTERFLY SHAPED COMPLEX [(MU-CH3TE)FE2(CO)6]2[MU-TE(CH2)TE-MU]

The new methylene bridged compound [(mu-CH3Te)Fe2(CO)6]2[mu-Te(CH2)Te-mu] has been prepared from the reaction at room temperature of Fe3(CO)9(mu-3-Te)2 and excess diazomethane. The compound was subjected to X-ray structural analysis. The crystals were monoclinic, space group C2/c, a = 28.865(10), b = 13.787(7), c = 14.733(4) A, beta = 104.67(2)-degrees, U = 5672 A3, Z = 8, D(c) = 2.637 g cm-3. The structure consists of two '(CO)6Fe2Te(CH3)Te' units connected by a CH2 group

Radiative effects of elevated aerosol layer in Central Himalayas

Systematic observations of light detection and ranging (LIDAR) to detect elevated aerosol layer were carried out at Manora Peak (29.4 degrees N, 79.5 degrees E, similar to 1960 m a.s.l), Nainital, in the Central Himalayas during January-May 2008. In spite of being a remote, high-altitude site, an elevated aerosol layer is observed quite frequently in the altitude range of 2460-4460 m a.s.l with a width of similar to 2 km during the observation period. We compare these profiles with the vertical profiles observed over Gadanki (13.5 degrees N, 79.2 degrees E, similar to 370 m a.s.l), a tropical station, where no such elevated aerosol layer was found. Further, there is a steady increase in aerosol optical depth (AOD) from January (winter) to May (summer) from 0.043 to 0.742, respectively, at Manora Peak, indicating aerosol loading in the atmosphere. Our observations show north-westerly winds indicating the convective lifting of aerosols from far-off regions followed by horizontal long-range transport. The presence of strongly absorbing and scattering aerosols in the elevated layer resulted in a relatively large diurnal mean aerosol surface radiative forcing efficiency (forcing per unit optical depth) of about -65 and -63 W m(-2) and the corresponding mean reduction in the observed net solar flux at the surface (cooling effect) is as high as -22 and -30 W m(-2). The reduction of radiation will heat the lower atmosphere by redistributing the radiation with heating rate of 1.13 and 1.31 K day(-1) for April and May 2008, respectively, in the lower atmosphere

Púrpura em paciente com estrongiloidíase disseminada Purpura in patient with disseminated strongiloidiasis

A infecção pelo Strongyloides stercoralis em associação com imunosupressão pode manifestar-se com lesões em múltiplos órgãos e sistemas, caracterizando a forma disseminada da doença. Lesões cutâneas não são freqüentemente relatadas e, se presentes, manifestam-se como rash e petéquias. Púrpuras bem definidas são pouco descritas. No presente trabalho é descrito um caso de estrongiloidíase disseminada, com acometimento cutâneo em forma de púrpura, que se desenvolveu em um paciente timectomizado e usuário crônico de corticosteróide devido à miastenia gravis.<br>The association of systemic corticosteroid therapy and dissemination of Strongyloides stercoralis has been increasingly documented in the literature. Skin involvement in disseminated strongyloidiasis has been reported and the most commonly described cutaneous manifestations are rash and petechial eruptions. We present a case of an immunosuppressed man that developed disseminated strongyloidiasis with extensive purpura